Introduction
S-1 is a novel oral anticancer drug, which was developed based on the biochemical modulation of tegafur (FT) by 5-chloro-2,4-dihydroxypyridine (gimeracil) and pot-Eastern Cooperative Oncology Group performance status of 0-2; (5) adequate organ function (white blood cell count, м3000/mm 3 ; absolute neutrocyte count, м2000/mm 3 ; platelet count, м100 000/mm 3 ; hemoglobin, м9.5 g/dl; transaminase level without liver metastases, Ϲ2.5 times upper normal limit, or with liver metastases, Ϲ3.0 times upper normal limit; total bilirubin, Ϲ1.5 mg/ dl; serum albumin, м3.0 g/dl; serum creatinine and blood urea nitrogen, Ϲupper normal limit). Presence of prior chemotherapy (including adjuvant chemotherapy) was not considered a criterion for exclusion. Treatment with S-1 started from May 1994 and continued to December 2000.
Treatment schedule
S-1 was provided by Taiho Pharmaceutical Company (Tokyo, Japan). The dose of S-1 was determined based on the body surface area (BSA) of the patient. The following doses were administered orally, twice daily, after breakfast and dinner; BSA, less than 1.25 m 2 , 40 mg; BSA 1.25-1.5 m 2 , 50 mg; BSA, 1.5 m 2 or more, 60 mg. One course of treatment consisted of 28 consecutive days' administration followed by 14 days' rest.
Treatment was interrupted or the doses were reduced after hematological toxicity of more than grade 3 or nonhematological toxicity of more than grade 2 appeared.
Assessment of responses and adverse reactions
The antitumor effects and adverse reactions were evaluated in accordance with the criteria of the Japanese Research Society for Gastric Cancer [11, 12] and the criteria of the Japan Society for Cancer Therapy [13] , which were established based on criteria established by the World Health Organization (WHO). The criteria to evaluate antiumor effects were as follows: complete response (CR), eradication of all cancers and maintenance of the condition for 4 weeks or more; partial response (PR), 50% or more reduction in size of lesions and maintenance of the condition for 4 weeks or more; no change (NC), less than 50% reduction in size of lesions or enlargement of lesions within 25% and maintenance of the condition for 4 weeks or more; progressive disease (PD), 25% or more enlargement of lesions or appearance of new lesions. Primary gastric lesions can be classified into three types: (a) measurable lesions, (b) evaluable but not measurable, and (c) diffusely infiltrating. Measurable lesions can be assessed by gastography with the patients in the same position for each procedure. Evaluable but not measurable lesions can be evaluated as a PR by improvements in gastrographic or endoscopic findings, or both, which are clearly different from pretreatment findings, e.g., showing a marked regression of tumors and ulcerations or marked flattening of evaluated lesions that can be estimated as a regression of more than 50% for 4 weeks or more. Diffusely infiltrating lesions can be evaluated by expansion of the affected gastric lumen, as seen by gastrography measured with a planimeter or a computer image analysis system before and after treatment. The gastrography must be done with the patient in the same position each time, using the same volume of barium and intake of air. PR after 4 or more weeks can be confirmed by enlargement of 50% or more of the affected area, compared with findings before treatment.
The overall response was evaluated from the WHO criteria. The response rate was defined as: response rate (%) ϭ (number of patients with CR and PR after treatment/number of patients who received treatment ) ϫ 100.
The survival time was calculated as the time from the start of treatment until death or final follow-up. The survival was calculated by statistical analysis, using the Kaplan-Meier method. Statistical analysis of differences between the survival curves were assessed by the generalized Wilcoxon test. Table 1 shows the clinical features of the 23 male and 6 female patients evaluated in this study. In regard to the state of the evaluable lesions, 13 patients had not had an operation, 4 had had an operation but were incurable and, 12 had recurrence of tumors after a previous curative operation. Twenty-one patients had no history of prior chemotherapy, and 8 patients had already received chemotherapy for recurrent lesions.
Results

Characteristics of the patients
Response rate and survival
All patients showed antitumor effects and some had adverse reactions. The mean number of treatments was 3.6 courses (range, 1-12 courses). Table 2 shows the antitumor activity of S-1 for all patients. PR was obtained in 37.9% of the patients (11 of 29). When the antitumor activity was evaluated according to the site of the disease, the response rate of primary tumors was 45.5% (5 of 11 patients); lymph nodes, 41.4% (7 of 17 patients); and liver metastasis, 30.0% (3 of 10 patients). Table 3 shows the antitumor activity of S-1 for the patients without prior chemotherapy. In this group, patients with marked antitumor activity had a response rate of 47.6% (10 of 21 patients). When antitumor activity was evaluated by site of disease, the response rate for primary tumors was 45.4% (5 of 11 patients), for lymph node, 54.5% (6 of 11 patients); and for liver metastases, 37.5% (3 of 8 patients). Table 4 summarizes the clinical response to S-1 in the 8 patients who had received other chemotherapy previously. The response rate was low: 12.5% (1 of 8 patients). The only patient in this group who showed PR was one with lymph node metastases who had previously received 5-FU ϩ methotrexate therapy. Figure 1 shows the survival of all patients. The 1-year and 2-year survivals of all patients were 50.2% and 24.3%, respectively. Figure 2 shows the survivals according to the response to the treatment. In patients who showed PR after S-1 treatment, 1-year and 2-year survivals were 89.2% and 64.3%, respectively. In patients who did not respond to treatment, 1-year survival was only 21.1%, and no patients survived for more than 2 years. The median survival time of all patients (n ϭ 29) was 14.1 months. The median survival time of patients who showed a PR (n ϭ 11) was 22.1 months, but in patients who failed S-1 treatment, it was only 6.0 months. Table 5 summarizes adverse reactions of all grades during and after the treatment. Adverse reactions occurred in 58.6% of patients (17 of 29). The most frequent adverse reaction was myelosuppression, such as leukocytopenia (34.3%; 10 of 29 patients), followed by neutrocytopenia (31.0%; 9 of 29 patients), and anemia (13.8%; 4 of 29 patients). For nonhematological toxicity, diarrhea (2 of 29 patients) and skin changes (2 of 29 patients) were most frequent. In all patients, only 2 experienced grade 3 toxicity (leukocytopenia and neutrocytopenia). No grade 4 adverse reactions appeared. There were no chemotherapy-related deaths.
Adverse reactions
Discussion
Continuous infusion is an effective method to administer 5-FU [14] [15] [16] [17] . Low-dose 5-FU and cisplatin (CDDP) treatment were frequently used in Japan in the 1990s because of low toxicity and high antitumor activity [18] [19] [20] . This treatment has the advantage of continuous infusion of 5-FU and biochemical modulation of CDDP [21] . Chung et al. [19] reported that, in a total of 26 patients with advanced or recurrent gastric cancer, the overall response rate was 50%, with 2 patients having a complete response (CR). The disadvantage of this treatment was longterm hospitalization during treatment.
S-1 is a novel oral anticancer drug, which was developed based on the biochemical modulation of FT by gimeracil and oteracil [1] [2] [3] [4] . Gimeracil strongly inhibits DPD, and inhibits 5-FU degradation approximately 180 times more effectively than uracil in vitro [7] . Coadministration of gimeracil and FT markedly increases the antitumor activity of FT. Oteracil inhibits the phosphorylation of 5-FU to 5-fluorouridine-5Ј-monophosphate. As oteracil is distributed in the gastrointestinal tract after oral administration, it possibly decreases 5-FU-induced gastrointestinal tract toxicity [4] . Thus, S-1 produces a prolonged plasma 5-FU concentration with reduced toxicity, and at the same time enables outpatient chemotherapy. Pharmacokinetically, with the standard drug dose (twice daily, after meals; BSA, Ͻ1. , 60 mg; consecutive 28-day administration and then 14 days' rest), the plasma 5-FU concentration is similar to that of continuous 5-FU infusion [22] .
Within the past 10 years, new anticancer drugs have been used in Japan. Response rates for single administration of these drugs were: irinotecan, 18.4% (14 of 76 patients); pirarubicin, 10.2% (5 of 49 patients); CDDP, 18.3% (13 of 71 patients); epirubicin, 14.7% (5 of 34 patients); and docetaxel, 23.7% (14 of 59 patients) [23- 25 ]. The response rates to S-1 in the two independent phase II studies of patients without prior chemotherapy were 49% and 44% [9, 10] . Our data showed that the response rate to S-1 in all patients was 37.9%. These data indicate that S-1 has the highest response rate after single-drug administration. When combined therapy frequently prescribed for advanced or recurrent gastric cancer was considered, FAMTX (5-FU ϩ adriamycin ϩ methotrexate [MTX]) therapy showed response rates of 21%-44% [26] [27] [28] [29] , ECF (epirubicin ϩ CDDP ϩ 5-FU) therapy showed response rates of 45%-46% [27, 28] , and 5-FU ϩ CDDP (FP) showed a response rate of 43% [30] . Thus, the antitumor effect of S-1 was comparable to these therapies. The median survival of patients treated by S-1 in our study was 14.1 months in all patients. Phase II studies of S-1 showed median survivals of 207 days and 250 days [9, 10] . Among other combined therapies, FAMTX showed a median survival of 5.7-8.7 months [26] [27] [28] [29] , FP showed 7.0 months [30] , and ECF showed 8.7-8.9 months [27, 28] . Because of the high response rate and longer survival, S-1 is surely a key drug in the treatment of advanced and recurrent gastric cancer.
For outpatient chemotherapy, a low incidence of severe adverse reactions is especially important. Our data showed that the frequency of adverse reactions of grade 3 or more was 6.9%, and this finding was consistent with frequencies of 4.0% and 5.9% of grade 3 or more adverse reactions in the previous phase II studies. From the viewpoint of safety, S-1 is appropriate for outpatient chemotherapy.
Although a high response rate to S-1 was reported for the phase II studies, these studies included only patients who had no evidence of prior chemotherapy. When only patients with a history of prior chemotherapy were considered, our study showed a low response rate (12.5%; one PR in eight patients). Thus, a new treatment strategy should be established. combined therapy of S-1 with other anticancer drugs is a future project to improve the response to chemotherapy. Although combined therapy with CDDP was investigated [31] , we are now focusing on the combined therapy of S-1 and taxotere. The following data support this concept: (1) combined 5-FU and a taxane (paclitaxel) in vitro was proved to show supra-additive effects [32] ; (2) 5-FU resistance was overcome by docetaxel in vitro [33] ; (3) clinically, taxotere was cytotoxic regardless of prior chemotherapy [24, 25] ; and (4) the cytotoxicity of S-1 was increased by docetaxel in a study using gastric cancer xenografts (Takahashi et al., unpublished data). A phase I study of combined S-1 and taxotere is ongoing. Another approach to improve survival may be to find factors that predict the response to S-1, as our data clearly showed a better survival of responders than of nonresponders (Fig. 2) . A definite conclusion cannot be made. Miyamoto et al. [34] retrospectively examined whether the immunoreactivity of thymidylate synthase and DPD in biopsy specimens could predict the response to S-1. Contrary to expectations, S-1 was effective, regardless of the immunohistochemical expression of both enzymes, in their study.
In conclusion, S-1 should be used as first-line chemotherapy for advanced and recurrent gastric cancer. The establishment of a strategy for second-line chemotherapy with S-1 and taxotere, and the identification of factors that predict responses are urgent tasks to improve the survival rate of patients.
